Roche delivers solid sales growth for the first nine months of 2014
Group sales up 5% at CER, stable in Swiss francs; 4% higher sales in Pharmaceuticals Division, with strong growth of oncology portfolio, as well as Actemra for rheumatoid arthritis and Xolair for asthma and chronic hives; 6% higher sales in Diagnostics Division, driven by strong Professional Diagnostics’ performance
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
More News: Actemra | Arthritis | Asthma | Cancer & Oncology | Hives | Pharmaceuticals | Rheumatoid Arthritis | Rheumatology | Xolair